GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » 3-Year EPS without NRI Growth Rate

Innovation Pharmaceuticals (Innovation Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 23.10% (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Innovation Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 23.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Innovation Pharmaceuticals was 43.20% per year. The lowest was -100.00% per year. And the median was -18.60% per year.


Competitive Comparison of Innovation Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Innovation Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Innovation Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Innovation Pharmaceuticals  (OTCPK:IPIX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Innovation Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Executives
Arthur Peter Bertolino officer: Pres. & Chief Medical Officer C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness officer: Vice President 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin director C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor director 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter director 7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich director, 10 percent owner, officer: Chief Financial Officer C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon director, 10 percent owner, officer: President-Chief Scient.Officer 10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans director, officer: Chief Executive Officer 17 IRVING PLACE, PELHAM NY 10803

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Headlines

From GuruFocus